Failure in the Development or Delay in the Commercialization of New Products or Technologies
First written in FY2016. 9 of 10 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2022: 2 of 13 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The consolidated companies are actively engaged in research and development, including by investing an amount equivalent to approximately 9% of recent revenue in research and development, and believe they can continue developing innovative and attractive new products. However, the process of developing and selling new products is complex and uncertain by nature,」
While continuing to invest approximately 9% of revenue in research and development, the company continues to disclose uncertainty related to new-product development and delays in commercialization. - FY2022-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The disclosure states that there have been no new occurrences or material changes regarding the risks of failure to develop new products or technologies or delays in commercialization. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The disclosure states that there have been no new occurrences or material changes regarding the risks of failure to develop new products or technologies or delays in commercialization. - FY2019RestatedAnnual report
「Products of consolidated companies may become obsolete as a result of rapid technological advances and changes in market needs. Delays in commercializing new technologies currently under development may cause the products to fall behind market demand.」
The risks related to delays in commercializing new technologies and product obsolescence are reaffirmed. - FY2018RestatedAnnual report
「Products of consolidated companies may become obsolete as a result of rapid technological advances and changes in market needs. Products may also fail to keep pace with market demand due to delays in commercializing new technologies currently under development.」
The risks related to delays in commercializing new technologies and product obsolescence are reaffirmed. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The disclosure states that there have been no new occurrences or material changes regarding the risks of failure to develop new products or technologies or delays in commercialization. - FY2018-Q2RestatedAnnual report
「No new business or other risks arose during the six-month cumulative period under review. There were also no material changes to the business and other risks described in the annual securities report for the previous consolidated fiscal year.」
The disclosure states that there have been no new occurrences or material changes regarding the risks of failure to develop new products or technologies or delays in commercialization. - FY2017RestatedAnnual report
「Products of consolidated companies may become obsolete as a result of rapid technological advances and changes in market needs. Products may also fail to keep pace with market demand due to delays in commercializing new technologies currently under development.」
The risks of failure to develop new products or technologies and delays in commercialization are reiterated. - FY2017-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The disclosure states that there have been no new occurrences or material changes regarding the risks of failure to develop new products or technologies or delays in commercialization. - FY2016First statedAnnual report
「Products of consolidated companies may become obsolete as a result of rapid technological advances and changes in market needs. Products may also fail to keep pace with market demand due to delays in commercializing new technologies currently under development.」
Uncertainty associated with research and development investment and the commercialization of new technologies is identified as a risk.